BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Contrave: Additional Phase III data

Additional data from a completer analysis of the double-blind, U.S. Phase III COR-I (NB-301) trial showed that 34.5% of patients in the high-dose (32 mg naltrexone SR/360 mg bupropion SR) Contrave group (n=296) achieved >=10% body weight loss vs. 10.7% for placebo (n=290) at week 56 (p<0.05). High-dose Contrave also significantly decreased waist...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >